Today at the Healthcare Information and Management Systems Society (HIMSS) conference in Florida, the Canadian subsidiaries of IBM and German pharmaceutical company Boehringer Ingelheim
announced plans to explore blockchain for clinical trials.
The companies plan to test whether blockchain can help with data integrity, the provenance of tests, transparency and patient empowerment. In 2017 Boehringer Ingelheim had revenues of $22 billion and is one of the world’s top 20 pharmaceutical companies.
Dr. Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) said: “The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment. Patients are at the heart of everything we do, so we are looking into novel solutions to improve patient safety and empowerment.”
Article continues …
Want the full story? Pro subscribers get complete articles, exclusive industry analysis, and early access to legislative updates that keep you ahead of the competition. Join the professionals who are choosing deeper insights over surface level news.
